According tomedia reports, through surgery or radiotherapy and other traditional means to treat prostate cancer there is a certain risk, some patients may appear impotence, urinary system problems and defecation difficulties and other side effects. Now, safer, less invasive treatments may soon be on the agenda, and MRI-guided ultrasound is one of them. The technique eliminated 80 percent of the subjects’ significant cancer symptoms in a one-year study.
The new technique, known as MRI, directs through urinary tract ultrasound ablation (TULSA), has actually been developed by researchers for years. This minimally invasive technique uses a stick that enters the prostate through the urethra and emits highly controlled sound waves, which can heat and destroy diseased tissue without harming healthy tissue.
It is reported that the ultrasound of the therapeutic rod comes from 10 built-in heating elements. Algorithmic researchers can control the shape, direction, and intensity of sound waves emitted by these components at any time. All of this is done in MRI scanners so doctors can keep a close eye on which tissue is heated and to what extent.
“Unlike other ultrasound systems on the market, you can monitor the ultrasonic ablation process in real time and immediately get MRI feedback on thermal doses and efficacy,” said Steven S. Raman, M.D., M.D., m.D., and co-author of the study. This is the shortest recovery time outpatient surgery. “
In one study, Raman and his team tested TULSA for TULSA in 155 men with low or moderate risk prostates. Each gland treatment took 51 minutes and was re-evaluated after 12 months.
Subsequent observations gave the researchers some very promising results. After one year of TULSA treatment, 80% of the subjects completely eliminated clinically significant cancer symptoms. Sixty-five percent of the subjects found cancer signs disappeared during their live tissue tests, while PSA, a key biomarker for prostate cancer, was reduced by an average of 95 percent.
In addition, patients receiving this kind of treatment after there are no reports of intestinal complications, while the rate of severe poisoning, impotence rate is also low, urinary incontinence problems are basically non-existent. In addition, the technology can also be used to treat other benign diseases such as prostate hypertrophy. Overall, the prostate volume of the subjects dropped from 39 cubic centimeters to 3.8 cubic centimeters after treatment.
“There are two very unique things about this system,” Raman says. Second, you can also use this therapy for diffuse and limited prostate cancer, as well as benign diseases, including benign hyperplasia. “
Now, scientists are working on further research to support this exciting outcome. TulSA has now received clinical approval in Europe, and recently obtained pre-market licenses from the FDA for safe and effective treatment of prostates in the United States and is expected to be clinically available in the United States in the near future.
Scientists are expected to present the findings this week at the annual meeting of the North American Society of Radiology.